

## Modifying the Protease, Antiprotease Pattern by Elafin Overexpression Protects Mice From Colitis

Jean-Paul Motta\*, Laurent Magne\*, Delphyne Descamps, Corinne Rolland, Camila Squarzoni-Dale, Perrine Rousset, Viviane Balloy, Michel Huerre, Dieter Jenne, Julien Wartelle, et al.

► **To cite this version:**

Jean-Paul Motta\*, Laurent Magne\*, Delphyne Descamps, Corinne Rolland, Camila Squarzoni-Dale, et al.. Modifying the Protease, Antiprotease Pattern by Elafin Overexpression Protects Mice From Colitis. *Gastroenterology*, WB Saunders, 2010, 140 (4), pp.1272-82. 10.1053/j.gastro.2010.12.050 . pasteur-00552947

**HAL Id: pasteur-00552947**

**<https://hal-pasteur.archives-ouvertes.fr/pasteur-00552947>**

Submitted on 6 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

## **Modifying the protease/anti-protease pattern protects from colitis in mice: benefits from elafin over-expression**

Jean-Paul Motta<sup>1,2\*</sup>, Laurent Magne<sup>3, 4, 5\*</sup>, Delphine Descamps<sup>3, 4</sup>, Corinne Rolland<sup>1, 2</sup>, Camila Squarzoni-Dale<sup>1,2</sup>, Perrine Rousset<sup>1, 2</sup>, Viviane Balloy<sup>3,4</sup>, Michel Huerre<sup>6</sup>, Dieter Jenne<sup>7</sup>, Julien Wartelle<sup>8</sup>, Azzaq Belaouaj<sup>8</sup>, Emmanuel Mas<sup>1, 2, 9</sup>, Jean-Pierre Vinel<sup>2, 10</sup>, Laurent Alric<sup>2, 10</sup>, Michel Chignard<sup>3, 4</sup>, Nathalie Vergnolle<sup>1,2\*</sup>, Jean-Michel Sallenave<sup>3, 4, 5\*</sup>

<sup>1</sup>INSERM U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse F-31300, France; <sup>2</sup>Université Toulouse III Paul Sabatier, Toulouse F-31000, France; <sup>3</sup>Institut Pasteur, Unité de Défense Innée et Inflammation, Paris, France; <sup>4</sup>INSERM U874, Paris, France; <sup>5</sup>UFR Sciences du Vivant, Université Paris Diderot, Paris, France; <sup>6</sup>Institut Pasteur, Unité de Recherche et d'Expertise Histotechnologie et Pathologie, Paris, France; <sup>7</sup>Department of Neuroimmunology, Max-Planck-Institute of Neurobiology, Martinsried, Munich, Germany; <sup>8</sup>EA 4303 "Inflammation and Immunity of the Respiratory Epithelium", CHU de Reims, Reims, France; <sup>9</sup>Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital, Toulouse, France; <sup>10</sup>Service d'Hepato-Gastro-Enterologie, Fédération Digestive, CHU Purpan, Toulouse, France.

\*Equal contribution

Correspondence: Reprint requests and correspondence should be addressed to either Nathalie Vergnolle or Jean-Michel Sallenave

Dr. Nathalie Vergnolle, INSERM U563, CHU Purpan, BP3028, 31024 Toulouse Cedex, France; tel : +33 (0)5 62 74 45 36, fax : +33 (0)5 62 74 45 28, E-mail : [nathalie.vergnolle@inserm.fr](mailto:nathalie.vergnolle@inserm.fr)

Pr. Jean-Michel Sallenave, Inserm U874, Institut Pasteur, 25, rue du Dr Roux, 75724 Paris Cedex 15, France, Tel. +33 (0)1 40 61 39 79; Fax +33 (0)1 45 68 87 03; E-mail : [jms@pasteur.fr](mailto:jms@pasteur.fr)

Short title: Elafin protects from colitis

Grant Support: Research supported by grants from the Bettencourt-Schueller Foundation and the INSERM-Avenir (to NV), the Schlumberger Foundation (to NV), the Agence

Nationale pour la Recherche (to NV), the Fondation pour la Recherche Medicale (to NV), the region Midi-Pyrenées (to JPM) and the Canadian Association of Gastroenterology (to CSD). LM holded an ATER position from the Université Paris 7-Diderot.

Author's contribution:

JP Motta: data acquisition, analysis and interpretation of data, drafting of the manuscript.

L Magne: data acquisition, analysis and interpretation of data, drafting of the manuscript.

D. Descamps: data acquisition, analysis and interpretation of data

C. Rolland: data acquisition, analysis and interpretation of data

C. Squarzoni-Dale: data acquisition, analysis and interpretation of data.

P. Rousset: data acquisition, analysis and interpretation of data.

V. Balloy: data acquisition, analysis and interpretation of data.

M. Huerre: data acquisition, analysis and interpretation of data.

D. Jenne: generation of NE/PR-3-deficient mice.

J. Wartelle: data acquisition and analysis of data.

A. Belaouaj: data analysis and interpretation of data

E. Mas: Biopsy collection, data acquisition

JP. Vinel: Biopsy collection, data acquisition

L. Alric: Biopsy collection, data acquisition

M. Chignard: critical revision of the manuscript for important intellectual content.

N. Vergnolle: study design, analysis and interpretation of data, manuscript drafting and editing, study supervision.

JM. Sallenave: study design, analysis and interpretation of data, manuscript drafting and editing, study supervision.

Disclosure: Authors have nothing to disclose.

**Number of words: 5,858**

**Abstract (225 words)**

**Background & Aims:** Increased proteolytic activity has been shown to be released from tissues of Inflammatory Bowel Disease (IBD) patients, but no studies have clearly addressed the role of the protease/anti-protease balance in the pathogenesis of colitis. We hypothesized that by changing the pattern of expression of protease inhibitors in the course of colitis, protective effects against the development of inflammation could be achieved. **Methods:** Using both a genetic approach with transgenic mice expressing human elafin, and mice genetically disrupted for the neutrophilic enzymes neutrophil elastase (NE) and proteinase-3 (PR-3), and a pharmacological approach by treating mice with replication-deficient adenovirus vector over-expressing human elafin, we investigated the effects of over-expressing human elafin, a low molecular weight molecule that potently and naturally inhibits NE and PR-3, during the course of colitis. **Results:** we showed that elafin expression/delivery re-equilibrated the proteolytic balance in mouse inflamed colon. In two IBD models (the trinitrobenzene sulfonic acid and the dextran sodium sulphate-induced colitis), transgenic mice expressing elafin and mice genetically disrupted for NE and PR-3 were protected from the development of colitis. Similarly, adenoviral delivery of elafin significantly inhibited inflammatory parameters. Elafin was able to modulate a variety of inflammatory mediators *in vitro* and *in vivo* and to strengthen intestinal epithelial barrier functions. **Conclusions:** these results

highlight elafin as a promising therapeutic agent for chronic intestinal inflammation such as IBD.

**Keywords:** Inflammatory Bowel Disease, Colitis, Proteases, Protease Inhibitors, Elafin, Inflammation.

### **Background and Aims**

In the setting of chronic inflammatory diseases such as Inflammatory Bowel Diseases (IBD), uncontrolled inflammatory response, ultimately leading to proteolytic tissue destruction constitutes the basis of the pathology. Although the aetiology of such diseases is not established yet, some mediators seem to play a prominent role in the pathogenesis of chronic inflammatory disorders. Recent studies have highlighted the role of proteases and their receptors in the pathogenesis of colitis<sup>1-4</sup>. In addition, an increased arginine-specific cleavage proteolytic activity has been shown to be released by tissues from IBD patients<sup>5</sup>. Surprisingly, the regulation of the protease/anti-protease balance in the gut has scarcely been addressed and the therapeutic potential of anti-protease supplementation seldom investigated. Proteolytic enzymes are largely released at sites of inflammation, by resident cells, infiltrated inflammatory cells, or by microorganisms. Concomitantly, endogenous protease inhibitors are synthesized and released within organs, maintaining a physiological proteolytic balance in tissues. Interestingly, in tissues from IBD patients, the expression of elafin and secretory leukocyte protease inhibitor, (two inhibitors of serine proteases expressed at mucosal surfaces and in the skin in inflammatory conditions in humans)<sup>6-12</sup> was shown to be attenuated upon inflammation<sup>13</sup>, thereby suggesting a disruption of the protease/anti-protease balance in

chronic inflammatory states of the gut. We therefore hypothesized that by changing the pattern of expression of protease inhibitors in the course of colitis, protective effects against the development of inflammation could be achieved. To that aim, we chose to investigate, during the course of colitis, the effects of over-expressing human elafin, one of the two inhibitors down-regulated in IBD. Human elafin is an efficient inhibitor of murine inflammatory proteases such as murine neutrophil elastase (NE) and proteinase-3 (PR-3)<sup>9</sup>, validating our present approach (henceforth in the manuscript, the term ‘elafin’ will always refer to the human ortholog). We used two different and independent strategies to over-express elafin into the mouse colon: a genetic strategy using mice transgenic for the expression of elafin and a pharmacological approach administering intracolonic elafin-expressing adenoviral (Ad) vector, henceforth called Ad-elafin<sup>14</sup>, in two different models of IBD. Further, in IBD models, we investigated inflammatory parameters in mice deficient for the expression of proteases (NE and PR-3)<sup>15</sup>.

These approaches allowed us to evaluate the general therapeutic effects of modifying the protease/anti-protease expression pattern in IBD, and in particular, to evaluate the therapeutic potential of elafin expression in the gut.

## **Methods**

### *Animals*

C57/Bl6 male mice (6-10 weeks) were either purchased from Janvier (Le Genest Saint Isle, France), or bred at the Institut Pasteur Animal Care facility for MCMV-elafin transgenics (MCMV-EL), Endothelin-elafin transgenics (Endo-EL) and littermates. MCMV-EL (elafin expressed under the mouse cytomegalovirus promoter) homozygotes mice were originally created on a mixed C57/Bl6 X CBA background<sup>16</sup> and Endo-EL mice (elafin expressed under the endothelin promoter) were originally obtained as heterozygous animals on a C57BL6 X SJL background<sup>17</sup>. Both strains were fully backcrossed (9 generations) on a pure C57BL6 background. Mice genetically disrupted for NE and PR-3 were bred at the faculty of medicine in Reims<sup>15</sup>. All animals were maintained under 12h-light/dark cycles having free access to food and water, except for being fasted the day before the induction of colitis. All procedures were approved by institutional animal care committees and veterinary services.

### *Induction of colitis*

Colonic inflammation in mice was induced by intracolonic administration of trinitrobenzene sulphonic acid (TNBS) (2 mg per mouse dissolved in 50% ethanol), or by addition to the drinking water of dextran sodium sulfate (DSS) (3 or 5%), as previously described<sup>1, 2</sup> (water consumption was equal in all groups for the DSS protocols). Body weight and survival rate were measured daily after the induction of colitis. Seven days after TNBS or DSS treatments, mice were sacrificed, and macroscopic score was assessed on whole colonic tissues, while samples were harvested for histology,

immunohistochemistry, myeloperoxidase (MPO) activity, cytokine expression and protease activity (trypsin-like and elastase/PR-3).

#### *Adenovirus constructs and in vivo treatments*

Ad-elafin, Ad-dl70-3 (referred hereafter as ‘Ad-null’, as it has no promoter, nor transgene) and Ad-I $\kappa$ B $\alpha$  are all replication-deficient adenovirus vectors which have been described before<sup>14</sup> and were amplified using well established protocols. Ad-NF- $\kappa$ B-luciferase was obtained from the Iowa Gene Transfer Vector Core (University of Iowa) at a titer of  $3.10^{10}$  pfu/ml and was diluted in PBS to obtain final working doses.

*In vivo* : Three days (for Ad-null and Ad-elafin) or 5 days (for Ad-NF- $\kappa$ B-luciferase) after drinking either water or DSS, each C57BL/6 male mice was anaesthetized and received intracolonicallly 100 $\mu$ l of PBS alone (vehicle) or either  $5.10^8$  pfu Ad-null or Ad5-elafin, or  $2.5.10^9$  pfu Ad-NF- $\kappa$ B-luciferase. The same treatment (water or DSS) was applied until day 7, when mice were sacrificed and tissues were collected for inflammatory parameter measurements, as described below.

#### *Assessment of inflammation*

Macroscopic damage scores were evaluated as previously described<sup>18-20</sup>. For microscopic damage, we chose to score (ranging from 0 to 10) the three more salient parameters, i.e epithelial cell injury, mucosal gland destruction and inflammatory cells infiltration in mucosa/submucosa<sup>18-20</sup>. MPO activity was measured as an index of granulocyte infiltration as previously described in colonic tissues harvested at the time of sacrifice<sup>18-20</sup>.



### *Serine protease activity in colonic tissues and luminal washes*

As previously described <sup>21</sup>, upon sacrifice, the entire colon was excised and 1ml PBS was instilled and washed twice through the lumen. A piece of colonic tissue was then kept and proteolytic activity (trypsin-like and elastase activity) were measured both in luminal washes and tissues. Trypsin-like and elastase/PR-3-like activities were measured using tosyl-Gly-Pro-Arg-*p*-nitroanilide (150µM, Sigma) and MeO-succinyl-Ala-Ala-Pro-Val-*p*-nitroanilide (100µM, Sigma, Saint Quentin Fallavier, France) respectively as substrates. Samples (20 µl for trypsin activity or 10 µl for elastase/PR-3 activity) were resuspended in their respective buffer : 100mM Tris/HCl, 1mM CaCl<sub>2</sub>, pH=8 for trypsin activity and 50 mM Tris-HCl, 500 mM NaCl, 0.1% Triton X100 for elastase/PR-3 activity. The change in absorbance at 405 nm was determined over 30-minutes at 37°C with a microplate reader NOVOstar™ (BMG Labtech, France). Activity was compared to known standard dilution of trypsin from porcine pancreas (Sigma) or human NE (Sigma). Protein concentration was determined using a BCA kit® (Pierce, Thermo Scientific, Courtaboeuf, France).

### *Cytokine expression*

Frozen colonic samples of transgenic and adenovirus treated mice were homogenized 30 seconds with a Polytron™ at 4°C in 500µl of cell lysis buffer (20mM Tris-Hcl, ph7.5, 150 mM NaCl, 1 mM Na<sub>2</sub>EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1mM beta-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 µg/ml leupeptin; Cell Signalling, Sigma) supplemented with anti-proteases (Roche Diagnostics, Meylan,

France) cocktail. After centrifugation (10000Xg, 10 min, 4°C), supernatants were filtered on QIAshredder columns (Qiagen, France). Fifty microliters of this homogenate was used for simultaneous dosage of KC (*keratinocyte chemoattractant*), MCP-1/CCL2 (*Monocyte chemoattractant proteins*), RANTES/CCL5 (*Regulated upon Activation, Normal T-cell Expressed, and Secreted*), TNF- $\alpha$ , IFN- $\gamma$ , Interleukins (IL) IL-2, IL-4, IL-5, IL-6, IL-10, IL-13 and IL-17A using *cytometric bead array* (CBA) on fluorescent cell sorter FACSCalibur according to the manufacturer's instructions (BD Biosciences, Le Pont de Claix, France). Raw values were normalized to tissue weight (average from 30 to 50 mg) and cytokine concentrations were extrapolated from standard curves with the help of FCAP Array® software. Only values above the limit of cytokine detection were considered.

#### *Measurement of NF- $\kappa$ B activity in vivo and bioluminescence*

Five days after starting water or DSS treatments, mice received Ad-NF- $\kappa$ B-luciferase intracolonicly. Two days later, mice received, an intra-peritoneal injection of D-Luciferin potassium salt (Synchem OHG, ref. BC219) (150mg/kg), 10-minutes before imaging. Mice were then kept anaesthetised under isoflurane inhalation in an IVIS CCD (charge-coupled device) camera coupled to the LivingImage software package (Xenogen, Biosciences, Cranbury, NJ). Bioluminescence signals were imaged during 20 minutes and a digital false-color photon emission image of the mouse was generated. Photons were counted within a constant defined area corresponding to the surface of the abdomen encompassing the whole colonic region. Photon emission was recorded as photons/second/cm<sup>2</sup>/steradian (p/s/cm<sup>2</sup>/sr) emitted. Images were analyzed and

quantified with Living Image® 3.0 (Xenogen) software.

#### *Histology, Immunohistochemistry, and in situ hybridization*

For histology, tissue samples from colons were fixed in 4% neutral buffered paraformaldehyde and embedded in paraffin. Five-micrometer sections were cut and stained with hematoxylin and eosin (H&E) for light microscopic examination. Microscopic damage scores were assessed on histological samples of colons by trained pathologists (M. Huerre, X. Zing) blinded from treatments. Cellular infiltration, epithelial cell ulceration and mucosal gland destruction were given scores ranging from 0 to 10, incremental scores denoting increased inflammation. See supplemental data for immunohistochemistry and *in situ* hybridization protocols.

#### *Cell culture*

Caco-2 cells were purchased from American Type Culture Collection (ATCC, Molsheim, France, HTB-37) and grown in Dulbecco's modified Eagle's medium Glutamax™ (DMEM, Invitrogen Cergy-Pontoise, France). The media was supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 100U/100µg penicillin/streptomycin (Invitrogen). Cultures were kept at 37°C in a 5% CO<sub>2</sub> environment and culture medium was changed every 2 days. Confluent cells were sub-cultured after Ca<sup>2+</sup>/Mg<sup>2+</sup> free PBS washes and partial digestion with trypsin (10 minutes, 37°C).

HT29 cells were cultured to sub-confluence in 6-well plates and were left either uninfected or were infected during 24hr with recombinant Ad vectors (Ad-null, Ad-elafin, Ad-IκBα, all at moi=5) in RPMI medium containing 0.5% of fetal calf serum.

Cells were then left unstimulated or were stimulated with bacterial LPS (final concentration 1 $\mu$ g/ml) or TNF- $\alpha$  (final concentrations 0.1 or 1 ng/ml). 24hr post stimulation, media were harvested and IL-8 protein secretion was measured by ELISA (R&D), following manufacturer's instructions.

#### *Paracellular permeability studies*

Caco-2 were grown as monolayer in 12-wells polycarbonate Transwell® plates (2.10<sup>5</sup> cells/well, 1.12cm<sup>2</sup> surface area of semi-permeable filter membrane) until confluence and permeability was measured as previously described<sup>22-24</sup>. Briefly, trans-epithelial resistance (TER) was measured every 3 days using an electrovoltage-meter (World Precision Instruments, France). After 21 days of culture (reaching TER>500  $\Omega$ .cm<sup>2</sup>), cells were exposed to apical and basolateral cytokines (TNF $\alpha$ , 10 ng/ml), PBS or Ad-elafin (all at moi =5) for 48 h. Apical and basolateral chamber contained 0.5 mL and 1.5 mL of medium, respectively. Paracellular permeability was assessed by apical-to-basal transport of a Dextran probe (MW3000) conjugated to fluorescein isothiocyanate (FITC). After treatments, dextran-FITC (100 $\mu$ M) was added into the apical chamber. After 2 h of incubation (37°C in 5% CO<sub>2</sub>), 300 $\mu$ l were collected from the basal chamber (triplicates) for fluoremetric measurement on a microplate reader NOVOstar™ with an excitation wavelength of 496 nm, emission at 524 nm, and cutoff at 515 nm. Paracellular permeability to Dextran-FITC was expressed as percentage of paracellular flux measured in untreated wells.

#### *Statistics*

Comparisons among groups were made using a 2-tailed Student's t test with Bonferroni correction. Data are expressed as mean  $\pm$  SEM, and a P value less than 0.05 was considered significant.

## Results

### *Proteolytic balance is modified by constitutive elafin expression during colitis*

We used here two elafin transgenic mouse lines, MCMV-EL and Endo-EL (which express elafin under the mouse cytomegalovirus and endothelin promoters, respectively, in a variety of tissues, including the gut (<sup>16, 17</sup>, and not shown)) to modify the protease/anti-protease expression pattern and consequently the proteolytic burden in mouse colon. Elafin expression in transgenic mice but not in wild-type littermates (WT) was detected by quantitative RT-PCR (Endo-EL: Ct 32±1; MCMV-EL: Ct / 30±2, and not detectable in WT) and was shown to be, largely expressed in the epithelium, when analyzed by FISH (see Supplementary Fig 1). We then investigated active protease levels in colonic tissues of elafin transgenic *versus* wild-type mice (WT). Elastase/PR-3 activity was detected in colonic tissues of mice drinking water and was not different in these basal non-inflamed conditions in wild-type or elafin-transgenic mice (both MCMV-EL and Endo-EL) (Fig. 1A). However, colitis induced either by DSS or TNBS provoked a significant increase in the activity of elastase/PR-3 in colons from WT mice (Fig. 1 A,B). This increase was significantly inhibited in elafin-transgenic mice (both MCMV-EL and Endo-EL) (Fig. 1 A,B), which showed levels similar to non-inflamed tissues. Similarly, trypsin-like activity was equivalent in all non-inflamed colonic tissues from WT, MCMV-EL, Endo-EL (Fig. 1 C, D). Seven days after the induction of colitis (by DSS or TNBS), trypsin-like activity was significantly increased in WT mice, but this increase was not observed in MCMV-EL, Endo-EL elafin-transgenic mice (Fig. 1 C, D). Similar patterns of elastase/PR-3 activity and trypsin-like activity were observed when

activity was measured in luminal lavages collected in PBS (data not shown). Taken together, these results showed that the expression of elafin did not modify basal elastase/PR-3 and trypsin-like activities, but was able to completely inhibit their increase upon the induction of colitis. Therefore, constitutive elafin transgenic expression modifies the protease/anti-protease balance in the colon during colitis, towards an inhibition of proteolytic activity.

*Elafin expression or NE-PR-3 deficiency protects from the development of colitis*

Colitis induced by DSS or intracolonic administration of TNBS provoked, as expected, several signs of inflammation, including weight loss (Supplementary Fig 2), macroscopic damage (DSS Fig. 2A, TNBS Fig 2B), and increased granulocyte infiltration (MPO activity in DSS Fig. 2C, TNBS Fig 2D). Compared to WT mice, transgenic mice constitutively expressing elafin (MCMV-EL and Endo-EL) showed a significant reduction in the observed inflammatory parameters. Macroscopic damage score was significantly reduced in both MCMV-EL and Endo-EL for both types of inflammatory insults (DSS Fig. 2A and TNBS Fig. 2B). MPO activity was significantly reduced both in MCMV-EL and Endo-EL mice when colitis was induced by either DSS (Fig. 2C), or TNBS (Fig. 2D). Microscopically, DSS colitis caused mostly mucosal injuries with epithelial cell destruction (arrows), mucus cell depletion and inflammatory cell infiltration mostly in the mucosa (arrow heads) (Fig. 3A). TNBS colitis caused transmural inflammation with muscle thickening (double arrows), goblet cell depletion, sometimes, crypt abscesses and transmural inflammatory cell infiltration (arrow heads) (Fig. 3A). In the DSS model, both MCMV-EL (Fig. 3B) and Endo-EL (Fig. 3C) showed less inflammation at the microscopic level than WT, with a most striking effect on

epithelial cell injury, mucosal gland destruction and inflammatory cell infiltration (Supplementary data Table 1). In the TNBS model, the inflammatory parameters mostly reduced in both elafin transgenic strains were the inflammatory cell infiltration, and to a lesser extent, mucosal gland destruction in Endo-EL mice (Table 1 Suppl.). Interestingly, we observed a strong expression of elafin in colonic biopsies from control subjects, mostly located in the epithelium. This expression was very weak in tissues from patients with Crohn's disease or ulcerative colitis (Supplementary Fig 3).

The pro-inflammatory role of NE and PR-3 was demonstrated in mice genetically disrupted for both enzymes. Heterozygote mice partly deficient for the expression of NE and PR-3 expressed significantly reduced amounts of colonic elastase/PR-3 activity (supplementary Fig 4) and were significantly protected against DSS-colitis, as assessed by macroscopic score and MPO levels (Supplementary Fig 4).

#### *Cytokine-Chemokine expression and release are modified by elafin expression*

In order to further investigate the effects of elafin expression on the modulation of innate immune responses, we measured the mRNA and protein levels of a variety of cytokines and chemokine from WT and elafin transgenic mouse colonic tissues in basal (non-inflamed) or colitis (DSS) conditions. mRNA levels of the chemokines KC, MIP1 $\alpha$ , MIP2, and RANTES were significantly reduced both in MCMV-EL and Endo-EL mice compared to WT mice after the induction of DSS colitis (Supplementary Table 2). At the protein level, among the cytokines analyzed, we observed that the levels of IL-6 and those of the neutrophil chemo-attractant proteins KC and IL-17A were significantly reduced in elafin-expressing mice (MCMV-EL) after colitis, when compared to WT mice



(Fig 3D). The protein levels of RANTES, TNF $\alpha$ , INF $\gamma$ , IL-2, MCP1 but also IL-4, IL-10, IL-5 or IL-13 (not shown) were unchanged between elafin transgenic mice and WT mice after colitis induction. Interestingly, RANTES mRNA was down-regulated in elafin transgenics (see Supplementary data, Table 2), suggesting post-transcriptional regulation.

#### *In vivo NF $\kappa$ B activation is modulated by Elafin*

Because the pro-inflammatory cytokines and chemokines expression analyzed are under the partial control of the nuclear factor NF- $\kappa$ B, we next tested whether NF- $\kappa$ B activity was modulated *in vivo* by elafin expression. Using a replication-deficient Ad-NF- $\kappa$ B-luciferase reporter system (Ad-NF- $\kappa$ B instilled intracolonicallly, Fig 4A) and bioluminescence *in vivo* recording, we showed for both murine elafin-expressing strains (MCMV-EL and Endo-EL), that elafin expression resulted in drastic down-regulation of NF- $\kappa$ B activity in the gut (Fig 4B, C). For those experiments, inflammatory parameters (macroscopic score, MPO, etc.) were also recorded and confirmed here again, that elafin transgenic mice (MCMV-EL and Endo-EL) had reduced inflammation (Fig 4D shows macroscopic damage scores). This also demonstrated that the use of the Ad vector had no confounding effects in our experimental system.

#### *A role for Elafin in epithelial functions: barrier and defense*

Intestinal epithelial cells constitute the very first line of defense in the course of colitis. First through its barrier function epithelium blocks the passage of luminal content into the tissues, and second, upon activation, by secreting chemokines such as the IL-8, it alerts the innate immune system, inducing thereby the recruitment of inflammatory cells.

Because elafin is strongly expressed at human epithelial surfaces, including that of the gut<sup>8, 13</sup>, we investigated the effects of elafin overexpression on those two major functions of the gut epithelium: barrier, and IL-8 secretion. Intestinal epithelial cells monolayers exposed to TNF $\alpha$  allowed the para-cellular passage of dextran. Incubation of cells with the adenoviral vector expressing elafin (Ad-elafin), but not with the null adenovector (Ad-null), induced a significant inhibition of TNF- $\alpha$  induced increased permeability (Fig. 5). For all conditions, changes in permeability could not be attributed to cell death as cell survival was the same in all groups (not shown). Intestinal epithelial cells stimulated either by TNF $\alpha$  or LPS released significant increased levels of IL-8 (Table 1). Treatment of those cells by Ad-elafin significantly reduced this release of IL-8, while Ad-null had no effect (Table 1). Remarkably, the extent of inhibition obtained by treatment of cells with Ad-elafin was similar to that conferred by Ad-I $\kappa$ B, an Ad vector coding for I $\kappa$ B, the canonical NF- $\kappa$ B inhibitor. Interestingly, in intestinal epithelial cells, Ad-elafin did not decrease, but instead significantly increased NF- $\kappa$ B activity (Table 1).

*Colonic Adenovirus-elafin expression in WT mice recapitulates the elafin protection observed in transgenic mice*

We also wanted to evaluate the therapeutic potential of transient delivery of elafin in the inflamed colon, and to investigate whether a transient re-equilibration of the balance proteases/anti-proteases, could modify the course of colitis. Intra-colonic administration of Ad-elafin to wild-type mice (natural ‘KO’ for the elafin gene, see above) after the induction of DSS colitis significantly reduced both elastase (Fig. 6A) and trypsin-like activity (Fig. 6B), while Ad-null had no effect. This decreased proteolytic activity in

tissues from inflamed mice treated with Ad-elafin was associated with a decreased macroscopic damage score (Fig. 6C), characteristic of protection against inflammation. At the microscopic level, mice treated with Ad-elafin showed significantly reduced mucosal injury and a preserved epithelium (Fig. 6D arrows), compared to mice that were treated with Ad-null or mice treated with vehicle.

These protective features were also associated with an impressive reduction in chemokines and pro-inflammatory cytokines in colonic tissues (Fig. 6E). TNF- $\alpha$ , IFN- $\gamma$ , IL-6, MCP-1 KC and IL-17 levels were all significantly increased in DSS-drinking mice, compared to water-drinking mice, and all those cytokines and chemokines were significantly reduced in tissues from mice treated with Ad-elafin, compared to mice treated with PBS or with Ad-null (Fig. 6E). Although RANTES levels were increased by the induction of colitis, this was not significantly reduced by Ad-null or Ad-elafin treatments. Colonic expression of IL-2, IL-4, IL-10, IL-5, and IL-13 were not different in Ad-elafin, Ad-null or PBS-treated mice after the induction of colitis by DSS (Fig. 6E and not shown). DSS-induced colitis disrupted the diffuse immunostaining of the zonula occludens tight junction protein ZO-1 provoking a rearrangement of this protein in clusters, in a pattern characteristic of intestinal epithelial barrier disruption. Ad-elafin, but not Ad-null treatment administered intra-colonically to DSS-treated mice largely maintained the diffuse immunostaining of ZO-1 in mouse colon (Supplementary Fig5). Interestingly, Ad-elafin treatment conferred no extra protection in mice genetically disrupted for NE and PR-3 expression (Supplementary Fig 6).

## **Discussion**

In the present study, we showed in different murine models of colitis that the proteolytic balance of tissues is disrupted towards an increased proteolytic activity, potentially providing mechanistic clues about what was previously observed in tissues from IBD patients<sup>5</sup>. Further, we established that restoring this proteolytic balance by the expression of the protease inhibitor elafin, in 3 independent models of over-expression (2 transgenic and 1 adenovirus-mediated expression) is associated with a strong protective effect against the development of colitis. These results not only provide definitive insights into the importance of the proteolytic balance in gut inflammation, but also point to a specific protease inhibitor: elafin, as a possible protective molecule in chronic inflammatory disorders of the gut.

Elafin is a specific inhibitor of NE and PR-3, two enzymes that are released by neutrophils<sup>9</sup>. In our study, whether elafin was expressed constitutively in transgenic mice, or transiently in Ad-elafin- treated mice, colitis-induced elastase/PR-3 and trypsin-like proteolytic activities in colonic tissues and luminal washes (not shown) were significantly inhibited (Fig. 1 and 6). The fact that mice deficient for NE and PR-3 are protected against colitis, and that elafin delivery by adenoviral vector (Ad-elafin) treatment did not confer further protection in those mice strongly suggest that elafin protection could be largely due to its inhibitory activity on elastase and PR-3. Because no inhibitory effect has ever been reported for elafin against trypsin-like enzymes, the decreased trypsin-like activity observed in elafin-expressing tissues could be due to indirect effects. Elafin, by inhibiting NE/PR-3 activity, could reduce a potential stimulatory effect of these enzymes on the production of trypsinogen/trypsin by colonic tissues. Elafin reduced not only

elastase/PR-3 and trypsin-like activities, but also the expression of several inflammatory genes that are, at least in part, under the control of NF- $\kappa$ B, therefore explaining the significant reduction in levels of pro-inflammatory cytokines and chemokines detected in our models. It is noteworthy, in keeping with the type 1 nature of the cytokine profiles triggered by TNBS and DSS at the observed time-points<sup>25</sup>, that elafin modulatory effects were limited to pro-inflammatory cytokines (IL-6, KC, IL-17, TNF- $\alpha$ , MCP-1) as well as to IFN- $\gamma$ , the prototypic type 1 cytokine, when elafin was administered via the adenoviral vector. We show here *in vivo* that elafin-expressing transgenic mice have strongly reduced levels of activated NF- $\kappa$ B after the induction of colitis compared to wild-type mice. Importantly, this is the first direct evidence for elafin of such activity on transcription factors *in vivo*, and more specifically, at sites of inflammation in the colon.

Many cell types could be theoretically targets of the anti-inflammatory properties of elafin in the gut, including monocytes, macrophages, and endothelial cells. Activation of all those cell types has been shown to be modulated by elafin expression (<sup>9, 26, 27</sup>, through inhibition of transcription factors<sup>26, 27</sup>, and could participate in synergy to the general anti-inflammatory properties of elafin. However, because elafin is primarily an epithelial cell product<sup>9</sup>, and because of the importance of intestinal epithelial cells in maintaining tissue homeostasis during colitis, we investigated whether this cell type could also be a target of elafin-induced protective properties. Our results show that in human intestinal epithelial cell lines, Ad-elafin was able to significantly decrease LPS and TNF $\alpha$ -induced IL-8 release (Table 1). Interestingly, this effect was not associated with a reduced, but instead with a significant increased epithelial NF- $\kappa$ B expression. This is in keeping with the notion that NF- $\kappa$ B activation plays an important protective role specifically in

epithelial cells, maintaining intestinal homeostasis<sup>28</sup>.. Therefore, these results suggest that depending on the cell types, elafin could either favour or inhibit NF- $\kappa$ B activation, with the overall goal to exert protection against inflammation. In addition, we also demonstrated here direct effects of elafin on epithelial cell permeability functions: Ad-elafin was able *in vitro* to significantly inhibit TNF $\alpha$ -induced increased intestinal monolayer<sup>29</sup> permeability (Fig. 5) and, *in vivo*, to restore tight junction organization, after DSS-induced colitis (Fig 5, Supplementary).

As indicated above, the protective effect of elafin could be mediated, at least in part, by tightening mucosal barrier. Indeed, intestinal mucosa permeability is considered a critical element of innate defense, and loss of the barrier function can lead to over-activation of immune cells<sup>30, 31</sup>. Indeed, upon epithelial barrier leakage, over-zealous luminal content-mediated activation of innate immune system has been implicated in the pathogenesis of IBD<sup>32</sup>. Taken together, our results provide the first evidence that re-equilibration of the proteolytic balance in the inflamed colon is associated with an impressive reduction in inflammatory parameters. Delivery and/or expression of the endogenous protease inhibitor elafin seem to be most effective to achieve a balanced proteolytic activity in the gut and to foster anti-inflammatory signals. Particularly noteworthy and impressive are results stemming from the Ad-elafin protocol which was designed as a ‘therapeutic’ approach, since the Ad-elafin vector was delivered locally 3 days after the onset of inflammation. These results highlight elafin as a strong potential therapeutic agent in the context of chronic intestinal inflammation such as IBD.

Acknowledgements:

The authors are indebted to Ms Brigitte Solhonne (Institut Pasteur/INSERM U874, Paris, France), Ms M-A Nicola (Institut Pasteur, Paris), Drs N. Cenac and L. Martin for technical assistance and advice and to Pr Z. Xing (McMaster University, Hamilton, Canada) for stimulating discussions and help during the study..

## **Figure legends**

### **Fig 1 Modulation of colonic protease activity by elafin after DSS- or TNBS-induced colitis.**

Male C57/Bl6 WT, MCMV-EL and Endo-EL mice drank either water (n= 9, 6, 5 respectively) or DSS (n= 11, 8, 8, respectively), or received intracolonic TNBS (n = 7, 5, 4 respectively) and were sacrificed 7-days later. Activity of elastase/PR-3 (A, B) and trypsin activity (C, D) were assessed in colonic extracts.

Significant differences compared to WT-inflamed is \* for  $p < 0.05$  and \*\*\* for  $p < 0.005$ .

### **Fig 2 Modulation of colonic macroscopic damage and MPO activity in elafin transgenic mice after DSS- or TNBS-induced colitis**

Male C57/Bl6 WT, MCMV-EL, Endo-EL mice (after H<sub>2</sub>O, DSS, or TNBS treatment) were assessed for colonic damage and MPO activity at day 7.

Significant differences compared to WT-inflamed group is \* for  $p < 0.05$ , \*\* for  $p < 0.01$ , and \*\*\* for  $p < 0.005$ .

### **Fig 3 Modulation of tissue architecture and pro-inflammatory cytokines in elafin transgenic mice after DSS- or TNBS-induced colitis**

Histology of colons (A-C) and cytokine protein content (D) from C57/Bl6 WT, MCMV-EL, Endo-EL mice, 7-days after H<sub>2</sub>O, DSS, or TNBS treatment. Scale bar is 20 $\mu$ m.

Significant differences compared to WT corresponding treatment is \* for  $p < 0.05$ .



**Fig 4 Modulation of *in vivo* NF- $\kappa$ B activity in elafin transgenic mice following DSS-mediated colitis**

Study design (A), luciferase bioluminescence measurements (B: pictures, C: quantification) and macroscopic damage score (D) in male C57/Bl6 WT, MCMV-EL and Endo-EL mice that drank H<sub>2</sub>O or DSS and received intracolonicly 2.5.10<sup>9</sup> pfu Ad-NF- $\kappa$ B-luciferase, 5-days after starting water or DSS treatments. Numbers represent mean +/- SD. \* represents statistical significance (p<0.05) compared to 'WT water', \*\* represents statistical significance (p<0.05) compared to 'WT DSS', \*\*\* represents statistical difference (p<0.005) compared to 'WT Adeno-NF $\kappa$ B + DSS' treated mice.

**Fig 5 Inhibition of TNF- $\alpha$ -stimulated permeability by Ad-elafin in intestinal epithelial cells**

Permeability (apical-to basal transport of a Dextran probe conjugated to FITC) was measured in Caco-2 cells grown as monolayer and exposed to apical and basolateral cytokines (TNF $\alpha$ , 10 ng/ml), and Ad-null or Ad-elafin (all at moi =5) for 48 h. Data (triplicate) are expressed as a percentage of paracellular flux compared to vehicle-treated cells and are representative of n=12 for the TNF group and n=6 for the TNF + Ad-EL group. Significant difference compared to TNF group was noted \* for p<0.05.

**Fig 6 Colonic Adenovirus-elafin expression in WT mice recapitulates the elafin protection observed in transgenic mice**

Three days after the induction of colitis by DSS (water was given to controls, n=5), male C57/Bl6 WT mice were injected intracolonicly with either PBS (n=8) or  $2.10^8$  pfu of either Ad-null (n=6) or Ad-elafin (n=7). Elastase/PR-3 (A), trypsin activity (B), colonic inflammation (C), histology (D), and cytokine content, (E) were assessed in tissues of those mice 7-days after the induction of colitis. For A-B, significant difference compared to PBS is \* for  $p<0.05$  and \*\* for  $p<0.01$ .  $\Psi$  represents significant difference compared to Ad-null group for  $p<0.05$ . In C, significant difference compared to PBS is \*\*\* for  $p<0.005$ .  $\Psi\Psi\Psi$  represents significant difference compared to Ad-null group for  $p<0.005$ . Scale bar is 20  $\mu\text{m}$  (D). In E, significant differences compared to DSS alone is \* for  $p<0.05$ .  $\Psi$  represents significant difference compared to DSS +Ad-null-treated group, for  $p<0.05$ .

**Table 1: Modulation of IL-8 secretion and NF- $\kappa$ B activity in colonic epithelial cells by Adenovirus-delivered elafin or I $\kappa$ B in response to stimulation by bacterial LPS or TNF- $\alpha$**

HT29 cells were treated or not (NI: non-infected) for 24hr with recombinant Ad vectors (Ad-null, Ad-elafin, Ad-I $\kappa$ B $\alpha$ , Ad-NF- $\kappa$ B-luciferase, all at moi =5), and were then stimulated or not with bacterial LPS (final concentration 1 $\mu\text{g}/\text{ml}$ ) or TNF- $\alpha$  (final concentrations 0.1 or 1 ng/ml). Twenty four hours later, IL-8 protein secretion was measured by ELISA in cell supernatants. Values represent mean IL-8 concentrations from 3 experiments, and SD are in brackets. NF- $\kappa$ B activity was measured in lysed cells, data were presented as firefly luciferase activities arbitrary units and expressed as an average of three independent experiments, SD are in brackets. \* denotes statistical significance ( $p<0.05$ ), compared to corresponding stimulation in Ad-null respective

conditions. # denotes statistical significance ( $p < 0.01$ ), compared to the corresponding non-infected (NI) cells.

#### Reference List

1. Hyun E, Andrade-Gordon P, Steinhoff M et al. Protease-activated receptor-2 activation: a major actor in intestinal inflammation. *Gut* 2008;57:1222-1229.
2. Vergnolle N, Cellars L, Mencarelli A et al. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. *J Clin Invest* 2004;114:1444-1456.
3. Vergnolle N. Clinical relevance of proteinase-activated receptors in the gut. *Gut* 2005;54:867-874.
4. Vergnolle N. Proteinase-activated receptors (PARs) in infection and inflammation in the gut. *Int J Biochem Cell Biol* 2008;40:1219-1227.
5. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. *J Clin Invest* 2007;117:636-647.
6. Hornsby MJ, Huff JL, Kays RJ et al. *Helicobacter pylori* induces an antimicrobial response in rhesus macaques in a cag pathogenicity island-dependent manner. *Gastroenterology* 2008;134:1049-1057.
7. Molhuizen HO, Alkemade HA, Zeeuwen PL et al. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. *J Biol Chem* 1993;268:12028-12032.
8. Sallenave JM, Ryle AP. Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. *Biol Chem Hoppe Seyler* 1991;372:13-21.
9. Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. *Am J Respir Cell Mol Biol* 2010;42:635-643.
10. Tremblay GM, Sallenave JM, Israel-Assayag E et al. Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. *Am J Respir Crit Care Med* 1996;154:1092-1098.

11. Wang Z, Chen F, Zhai R et al. Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. *PLoS One* 2009;4:e4380.
12. Wiedow O, Luademann J, Utecht B. Elafin is a potent inhibitor of proteinase 3. *Biochem Biophys Res Commun* 1991;174:6-10.
13. Schmid M, Fellermann K, Fritz P et al. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. *J Leukoc Biol* 2007;81:907-915.
14. Sallenave JM, Xing Z, Simpson AJ et al. Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. *Gene Ther* 1998;5:352-360.
15. Kessenbrock K, Frohlich L, Sixt M et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. *J Clin Invest* 2008;118:2438-2447.
16. Sallenave JM, Cunningham GA, James RM et al. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. *Infect Immun* 2003;71:3766-3774.
17. Zaidi SH, Hui CC, Cheah AY et al. Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. *J Clin Invest* 1999;103:1211-1219.
18. Cattaruzza F, Cenac N, Barocelli E et al. Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents. *Am J Pathol* 2006;169:177-188.
19. Cenac N, Coelho A, Nguyen C et al. Induction of intestinal inflammation in mouse by activation of Proteinase-Activated Receptor-2. *Am J Pathol* 2002;161:1903-1915.
20. Cenac N, Cellars L, Steinhoff M et al. Proteinase-activated Receptor-1 is an Anti-inflammatory Signal for Colitis Mediated by a Type 2 Immune Response. *Inflamm Bowel Dis* 2005;11:792-798.
21. Hansen KK, Sherman PM, Cellars L et al. A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. *Proc Natl Acad Sci U S A* 2005;102:8363-8368.
22. Cenac N, Chin AC, Garcia-Villar R et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways. *J Physiol* 2004;558:913-925.

23. Chin AC, Vergnolle N, Macnaughton WK et al. Proteinase-activated receptor-1 induces apoptosis and increases intestinal permeability. *Proc Natl Acad Sci U S A* 2003;100:11104-11109.
24. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. *Gut* 2009;58:196-201.
25. Kirsner JB. *Inflammatory Bowel Disease*. W.B. Saunders company, 2000.
26. Butler MW, Robertson I, Greene CM et al. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. *J Biol Chem* 2006;281:34730-34735.
27. Henriksen PA, Hitt M, Xing Z et al. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. *J Immunol* 2004;172:4535-4544.
28. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. *Nat Rev Immunol* 2009;9:778-788.
29. Simpson AJ, Maxwell AI, Govan JR et al. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. *FEBS Lett* 1999;452:309-313.
30. Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008;134:577-594.
31. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. *World J Gastroenterol* 2008;14:401-407.
32. Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. *Proc Natl Acad Sci U S A* 2005;102:18129-18134.